For triple-negative breast cancer (TNBC), the use of MEK inhibitors has enhanced the responses to immune checkpoint blockade, with an upregulation of MHC I and II on tumor cells, increase in CD8 TILs, and improved prognosis [88]. The gene discussed is CD8A; the disease is neoplasm.